Phase I Study of MEDI-534 of a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus and Parainfluenza-3 Virus in Seropositive Children

Authors

Margarita Gomez
Maurice A. Mufson, Marshall UniversityFollow
Filip Dubovsky
Conor Knightly
Wen Zeng
Genevieve Losonsky

Document Type

Article

Publication Date

7-2007

Abstract

A live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine was evaluated in healthy respiratory syncytial virus/parainfluenza virus type 3 seropositive children aged 1 to 9 years. Three cohorts of 40 children were randomized 1:1 to receive 10^4, 10⁵ or 10⁶ median tissue culture infectious dose₅₀ MEDI-534 vaccine of placebo. The vaccine's safety profile was similar to placebo, no viral shedding was detected, and the vaccine was minimally immunogenic.

Comments

This article first appeared in the July 2009 issue of The Pediatric Infectious Disease Journal, and is reprinted with permission.

©2009 Wolters Kluwer Health

Recommended Citation

Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. “Phase I study of MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children,” The Pediatric Infectious Disease Journal. 2009 July 28(7):655-8.